Are treat-to-target and dose tapering strategies for rheumatoid arthritis possible during the COVID-19 pandemic?
作者信息
Yeoh Su-Ann, Ehrenstein Michael R
机构信息
Centre for Rheumatology, Division of Medicine, University College London, London WC1E 6JF, UK.
出版信息
Lancet Rheumatol. 2020 Aug;2(8):e454-e456. doi: 10.1016/S2665-9913(20)30175-2. Epub 2020 Jun 8.
Abstract
摘要
相似文献
1
Are treat-to-target and dose tapering strategies for rheumatoid arthritis possible during the COVID-19 pandemic?
Lancet Rheumatol. 2020 Aug;2(8):e454-e456. doi: 10.1016/S2665-9913(20)30175-2. Epub 2020 Jun 8.
2
[Discontinuation or tapering strategies of biologics in rheumatoid arthritis in remission].
Rev Med Interne. 2017 Apr;38(4):256-263. doi: 10.1016/j.revmed.2016.12.014. Epub 2017 Feb 1.
3
Tapering biologics in rheumatoid arthritis: a pragmatic approach for clinical practice.
Clin Rheumatol. 2017 Jan;36(1):1-8. doi: 10.1007/s10067-016-3490-8. Epub 2016 Nov 28.
4
Biological tapering and sonographic flare in rheumatoid arthritis.
J Investig Med. 2018 Feb;66(2):325-328. doi: 10.1136/jim-2017-000558. Epub 2017 Sep 20.
5
Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the Imact of esidual Inflammation Detected via Imaging Tchniques, rug Levels and Patient Characteristics on the Outcome of Dose Taperng of Adalimumab in linical Remission Rheumatoid Arhritis () patients (PREDICTRA).
BMJ Open. 2018 Feb 28;8(2):e019007. doi: 10.1136/bmjopen-2017-019007.
6
Cost-effectiveness of five different anti-tumour necrosis factor tapering strategies in rheumatoid arthritis: a modelling study.
Scand J Rheumatol. 2019 Nov;48(6):439-447. doi: 10.1080/03009742.2019.1613674. Epub 2019 Jun 21.
7
Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study.
Ann Rheum Dis. 2019 Jun;78(6):746-753. doi: 10.1136/annrheumdis-2018-214970. Epub 2019 Apr 6.
8
Therapeutic strategy for rheumatoid arthritis patients who have achieved remission.
Joint Bone Spine. 2018 Dec;85(6):679-685. doi: 10.1016/j.jbspin.2018.02.002. Epub 2018 Feb 13.
9
A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes.
Rheumatology (Oxford). 2017 Jun 1;56(6):973-980. doi: 10.1093/rheumatology/kex003.
10
Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trial.
RMD Open. 2017 Sep 12;3(2):e000474. doi: 10.1136/rmdopen-2017-000474. eCollection 2017.
引用本文的文献
1
The synergistic efficacy of hydroxychloroquine with methotrexate is accompanied by increased erythrocyte mean corpuscular volume.
Rheumatology (Oxford). 2022 Feb 2;61(2):787-793. doi: 10.1093/rheumatology/keab403.
本文引用的文献
1
Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study.
Ann Rheum Dis. 2020 Aug;79(8):1023-1030. doi: 10.1136/annrheumdis-2020-217246. Epub 2020 May 13.
2
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies.
Ann Rheum Dis. 2020 May;79(5):667-668. doi: 10.1136/annrheumdis-2020-217424. Epub 2020 Apr 2.
3
Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM).
Ann Rheum Dis. 2020 Apr;79(4):453-459. doi: 10.1136/annrheumdis-2019-216819. Epub 2020 Feb 24.
4
Conventional versus ultrasound treat to target: no difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis.
Rheumatology (Oxford). 2020 Sep 1;59(9):2550-2555. doi: 10.1093/rheumatology/kez674.
5
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
Ann Rheum Dis. 2020 Jun;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655. Epub 2020 Jan 22.
6
Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice.
RMD Open. 2019 Nov 28;5(2):e001050. doi: 10.1136/rmdopen-2019-001050. eCollection 2019.
7
Can we wean patients with inflammatory arthritis from biological therapies?
Autoimmun Rev. 2019 Dec;18(12):102399. doi: 10.1016/j.autrev.2019.102399. Epub 2019 Oct 19.
8
Remission vs low disease activity: function, quality of life and structural outcomes in the Early Rheumatoid Arthritis Study and Network.
Rheumatology (Oxford). 2020 Jun 1;59(6):1272-1280. doi: 10.1093/rheumatology/kez461.
9
Dual target strategy: a proposal to mitigate the risk of overtreatment and enhance patient satisfaction in rheumatoid arthritis.
Ann Rheum Dis. 2019 Oct;78(10):e109. doi: 10.1136/annrheumdis-2018-214199. Epub 2018 Aug 20.
10
Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis.
Rheumatol Int. 2018 Jun;38(6):935-947. doi: 10.1007/s00296-018-4005-5. Epub 2018 Mar 21.
Zotero 插件